Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751589 · ClinicalTrials.gov registry record · Early Phase 1
A Study of a Weight Loss Intervention in People With Endometrial Cancer
A Early Phase 1 study of Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT06751589 is a Early Phase 1 study of Endometrial Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 36 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06751589, a Early Phase 1 study of Endometrial Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (7)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06751589
The ClinicalTrials.gov registry entry for NCT06751589 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06751589 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06751589 about?
NCT06751589 is a clinical study titled "A Study of a Weight Loss Intervention in People With Endometrial Cancer". The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the ...
What is the current status of trial NCT06751589?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2024-12-19. Estimated completion is 2026-12.
What conditions does trial NCT06751589 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06751589?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06751589?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06751589 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
RECRUITING · Early Phase 1
-
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
RECRUITING · Early Phase 1
-
A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium
COMPLETED · Early Phase 1
-
Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer
COMPLETED · Early Phase 1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
The Better, Harder, Faster, Stronger Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.